Patent
BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS
Bruno Stuhlmeuller,Gerd Reudiger Burmester +1 more
- 30 May 2008
82
TL;DR: In this paper, a method for predicting responsiveness to TNFα inhibitors in a subject suffering from an autoimmune disorder, such as rheumatoid arthritis, is presented. But the method is based on the CD11c biomarker.
read more
Abstract: The invention provides methods for predicting responsiveness to TNFα inhibitors in a subject suffering from an autoimmune disorder, such as rheumatoid arthritis. The methods involve assaying for expression of one or more biomarkers in the subject that are predictive of responsiveness to TNFα inhibitors. A preferred biomarker of the invention is CD11c. The methods can further comprise selecting a treatment regimen with a TNFα inhibitor in an autoimmune disorder subject based upon expression of the biomarker(s) in the subject. The methods can further comprise administering a TNFα inhibitor to the subject according to the selected treatment regimen. Kits that include means for measuring expression of one or more biomarkers that are predictive of responsiveness to TNFα inhibitors for an autoimmune disorder are also provided. Methods of preparing and using databases, and computer program products therefore, for selecting an autoimmune disorder subject for treatment with a TNFα inhibitor are also provided.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Patent
Formulation of human antibodies for treating tnf-alpha associated disorders
Hans-Juergen Krause,Lisa Baust,Michael Dickes +2 more
- 14 Aug 2015
TL;DR: In this article, a liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability, which is similar to our formulation.
157
Patent
TREATMENT OF TNFAlpha RELATED DISORDERS
Subhashis Banerjee,Lori K. Taylor,Clive E. Spiegler,Daniel E. Tracey,Elliot K. Chartash,Rebecca S. Hoffman,William T. Barchuk,Philip Yan,Anwar Murtaza,Jochen G. Salfeld,Steven Fischkoff +10 more
- 02 May 2014
TL;DR: Methods of treating TNFα-related disorders comprising administering tNFα inhibitors, including TNFβ antibodies, are described in this paper, where the authors also describe the use of immunoglobulin (Iglesias et al.
143
Patent
Human antibodies that bind human TNFa
Jochen G. Salfeld,Allen Deborah J,Hoogenboom Hendricus R J M,Zehra Kaymakcalan,Boris Labkovsky,John A. Mankovich,Brian T. Mcguinness,Roberts Andrew J,Paul Sakorafas,David Schoenhaut,Tristan J. Vaughan,Michael White,Alison Jane Wilton +12 more
- 17 Apr 2007
TL;DR: In this paper, an isolated human anti-human TNF-alpha antibody comprising of a light chain variable region (LCVR) comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3 (QRYNRAPYT/A), CDR 2 domain comprising amino acid sequences from SEQID NO: 4 (VSYLSTASSLDY/N), and CDR 1 domain consisting of amino acid amino acids from SEqID No. 6 (AITWNSGHIDYADSVEG) and SEQ No.
142
Patent
Protein formulations and methods of making same
Wolfgang Fraunhofer,Annika Bartl,Hans-Juergen Krause,Markus Tschoepe,Katharina Kaleta +4 more
- 28 Nov 2008
TL;DR: In this paper, an aqueous formulation comprising water and a protein, and methods of making the same, is described, and the formulation may be a high protein formulation and/or may have low levels of conductivity resulting from the low level of ionic excipients.
136
Patent
Crystalline anti-htnfalpha antibodies
David W. Borhani,Wolfgang Fraunhofer,Hans-Juergen Krause,Anette Koenigsdorfer,Gerhard Winter,Stefan Gottschalk +5 more
- 25 Oct 2007
TL;DR: In this article, a batch crystallization method for crystallizing an anti-hTNFα antibody which allows the production of said antibody on an industrial scale was presented; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.
133
References
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Ravinder N. Maini,E W St Clair,F. C. Breedveld,Daniel E. Furst,Joachim R. Kalden,Michael H. Weisman,Josef S. Smolen,Paul Emery,G Harriman,Marc Feldmann,Peter E. Lipsky +10 more
TL;DR: Infliximab was well-tolerated; withdrawals for adverse events as well as the occurrence of serious adverse events or serious infections did not exceed those in the placebo group.
2.5K
Antibody-antigen Interactions: Contact Analysis and Binding Site Topography
TL;DR: Antigen-contacting propensities are presented for each antibody residue, allowing a new definition for the complementarity determining regions (CDRs) to be proposed based on observed antigen contacts.
1.9K
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial
Jürgen Braun,J. Brandt,Joachim Listing,A. Zink,Rieke Alten,W. Golder,E Gromnica-lhle,Herbert Kellner,A Krause,Matthias Schneider,H Sörensen,Henning Zeidler,W Thriene,Joachim Sieper +13 more
TL;DR: The results show that treatment with infliximab is effective in patients with active ankylosing spondylitis, and since there are some potentially serious adverse effects, it is recommended that this treatment mainly be used in co-operation with rheumatological centres.
1.3K
A peptide mimetic of an anti-CD4 monoclonal antibody by rational design
Florence Casset,Florence Roux,Patrick Mouchet,Cédric Bès,Thierry Chardès,Claude Granier,Jean-Claude Mani,Martine Pugnière,Daniel Laune,Bernard Pau,Michel Kaczorek,Roger Lahana,Anthony R. Rees +12 more
TL;DR: Using peptide mapping to determine 'active' antigen recognition residues, molecular modeling, and a molecular dynamics trajectory analysis, a peptide mimic of an anti-CD4 antibody is developed, containing antigen contact residues from multiple CDRs.
1K
Patent
Dual variable domain immunoglobulins and uses thereof
Chengbin Wu,Tariq Ghayur,Richard W. Dixon,Jochen G. Salfeld +3 more
- 18 Aug 2006
TL;DR: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
900